Want to see HK:2291 full AI Analyst Report?
2291 Stock Chart & Stats
HK$13.57
HK$0.14(1.03%)
At close: 4:00 PM EDT
HK$13.57
HK$0.14(1.03%)
Day’s Range― - ―
52-Week RangeHK$8.33 - HK$21.22
Previous CloseN/A
Volume1.90M
Average Volume (3M)1.14M
Market Cap
HK$3.92B
Enterprise ValueHK$2.04K
Total Cash (Recent Filing)HK$1.29B
Total Debt (Recent Filing)HK$1.40M
Price to Earnings (P/E)17.1
Beta1.04
Next Earnings
Mar 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.85%
Share Statistics
EPS (TTM)0.59
Shares Outstanding344,694,000
10 Day Avg. Volume299,964
30 Day Avg. Volume1,138,655
Financial Highlights & Ratios
PEG Ratio-7.43
Price to Book (P/B)2.46
Price to Sales (P/S)9.49
P/FCF Ratio34.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.03
Revenue Forecast (FY)HK$751.00M
Bulls Say, Bears Say
Bulls Say
High ProfitabilityVery high gross and operating margins indicate strong underlying profitability and provide substantial room to absorb cost pressure. The approximately 46% net margin reported for 2025 demonstrates significant earnings power, supporting reinvestment and financial resilience over the next several quarters.
Exceptionally Conservative Balance SheetMinimal debt and an extremely low debt-to-equity ratio reduce financial risk and interest-related pressure. Sizable equity and assets that have generally grown provide resilience, preserve funding flexibility, and allow the company to support operations without relying heavily on external borrowing.
Improving Cash GenerationConsistently positive operating cash flow and stronger free cash flow through 2023–2025 indicate that the business is converting operations into funding more effectively. This supports internal investment capacity, dividend support, and greater flexibility during periods of uneven earnings.
Bears Say
Recent Revenue ContractionThe 2025 revenue decline shows that demand or business momentum weakened after strong expansion from 2020 to 2024. A sustained contraction could reduce operating leverage, limit reinvestment capacity, and make the company more dependent on margin strength to protect earnings.
Historical Earnings VolatilityThe 2022 net loss, followed by a strong rebound, demonstrates that profitability can be sensitive in weaker periods despite currently high margins. This history makes future earnings less predictable and increases the importance of maintaining revenue momentum and operational execution.
Inconsistent Cash ConversionFree cash flow trailing reported profit in many periods suggests that accounting earnings do not always translate into available cash at the same rate. Negative free cash flow in 2022 also indicates periodic working-capital or investment pressure, which can constrain shareholder returns and funding flexibility.
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H News
2291 FAQ
What was LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H’s price range in the past 12 months?
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H lowest stock price was HK$8.33 and its highest was HK$21.22 in the past 12 months.
What is LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H’s market cap?
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H’s market cap is HK$3.92B.
When is LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H’s upcoming earnings report date?
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H’s upcoming earnings report date is Mar 26, 2027 which is in 183 days.
How were LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H’s earnings last quarter?
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H released its earnings results on Aug 21, 2026. The company reported HK$0.495 earnings per share for the quarter.
Is LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H overvalued?
According to Wall Street analysts LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H’s price is currently Overvalued.
Does LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H pay dividends?
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H pays a Annually dividend of HK$0.573 which represents an annual dividend yield of 4.85%. See more information on LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H dividends here
What is LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H’s EPS estimate?
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H have?
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H has 344,694,000 shares outstanding.
What happened to LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H’s price movement after its last earnings report?
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H reported an EPS of HK$0.495 in its last earnings report. Following the earnings report the stock price went up 20.525%.
Which hedge fund is a major shareholder of LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2291
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.02%
12-Months-Change
Fundamentals
Return on Equity
4.85%
Trailing 12-Months
Asset Growth
3.89%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd., an investment holding entity, focuses globally on the research, development, production, and marketing of advanced interventional medical devices. The company provides an extensive range of solutions addressing various cardiovascular ailments. This includes specialized treatments for congenital heart defects, such as occluders for atrial septal, ventricular septal, and patent ductus arteriosus, along with necessary delivery systems and snare products. Additionally, it develops technologies for preventing cardioembolic stroke, offering occluders for the left atrial appendage and patent foramen ovale. Its portfolio also features a comprehensive selection of products for managing valvular diseases, including devices for aortic, mitral, tricuspid, and pulmonary valves, complemented by essential procedural accessories. Further offerings encompass vascular plugs and interatrial shunt devices. These medical technologies are primarily distributed to hospitals and through a network of distributors. Founded in 1994, the firm is headquartered in Shanghai, People's Republic of China, and operates as a subsidiary of Lepu Medical Technology (Beijing) Co., Ltd.
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H (2291) Earnings & Revenues
Technical Analysis
Neusoft Education Technology Co. Limited
―
China Leon Inspection Holding Limited
―
REF Holdings Limited
―
Cornerstone Technologies Holdings Limited
―
EDICO Holdings Limited
―